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Abstract
Aims: Public Health England have identified that in coronavirus disease 2019 (COVID-19), death rates 
amongst ethnic minorities far exceeds that of the White population. Whilst the increase in ethnic 
minorities is likely to be multi-factorial; to date, no studies have looked to see whether values for 
routine clinical biochemistry parameters differ between ethnic minority and White individuals.  
Methods: Baseline biochemical data for 22 common tests from 311 SARs-CoV-2 positive patients 
presenting to hospital in April 2020 in whom ethnicity data was available was retrospectively collected 
and evaluated. Data comparisons between ethnic minority and White groups were made for all 
patient data and for the subset of patients subsequently admitted to intensive care. 
Results: When all patient data were considered, the ethnic minority population had statistically 
significant higher concentrations of CRP, AST and GGT, whilst troponin T was higher in the White 
group. A greater proportion of ethnic minority patients were subsequently admitted to intensive care, 
but when the presenting biochemistry of this subset of patients was compared, no significant 
differences were observed between ethnic minority and White groups.   
Conclusion: Our data show for the first time that routine biochemistry at hospital presentation in 
COVID-19 differs between ethnic minority and White groups. Amongst the markers identified, CRP 
was significantly higher in the ethnic minority group pointing towards an increased tendency for 
severe inflammation in this group. 
Keywords: SARs-CoV-2, COVID-19, ethnic minority, ethnicity, routine biochemistry
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BMI, body mass index; CK, creatine kinase; CKD, chronic kidney disease; COPD, 
chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; 
Page 4 of 19
https://mc.manuscriptcentral.com/jclinpathol





























































Confidential: For Review Only
CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GGT, gamma-
glutamyltransferase; IL-6, interleukin-6; ITU, intensive care unit; LDH, lactate dehydrogenase; NT-
proBNP, N-terminal prohormone of brain natriuretic peptide; SARS-CoV-2, severe acute respiratory 
syndrome coronavirus 2.
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Introduction
In December 2019 a new highly infectious disease, coronavirus disease 2019 (COVID-19), was first 
reported in Wuhan, Hubei Province, China.1,2 The causative agent of COVID-19, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), has since spread worldwide resulting in 88 387 352 
cases and 1 919 204 deaths as of January 10 2021, according to a weekly epidemiological update from 
the World Health Organization.3
Severe or fatal COVID-19 infection has been associated with gross changes in Clinical Biochemistry 
parameters.  To date, common findings include increases of markers of tissue damage (creatine kinase 
(CK), lactate dehydrogenase (LDH), myoglobin, troponin), inflammation (C-reactive protein (CRP), 
ferritin, procalcitonin), renal impairment (increased creatinine and urea) and liver dysfunction 
(increases of amino transferases and bilirubin, decreased albumin).4,5 Severe COVID-19 infection has 
also been associated with low serum sodium, potassium and calcium.6 Biochemical data can be 
predictive in COVID-19; parameters which are predictive of death include increased CRP, LDH, 
aspartate aminotransferase (AST), troponin I and creatinine and low albumin.7-10 
In a review by Public Health England, death rates amongst Black, Asian and other minority ethnicities 
COVID-19 positive people were shown to be significantly higher than in White British people.11 Death 
rates in those of Bangladeshi background were twice as high, and for other ethnic minority groups 
between 10-50% higher, after taking into account age, sex, deprivation, and region. The cause of these 
discrepancies is unclear, but likely to be multifactorial. We have previously assessed differences in 
cardiac markers at hospital presentation in ethnic minority and White groups in COVID-1912, but to 
date, no study has investigated whether more routine biochemistry broadly differ in this setting, nor 
whether any differences provide prognostic value. To address these questions, we retrospectively 
reviewed admission biochemistry for a cohort of COVID-19 positive patients in whom ethnicity data 
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was available. We compared all data between ethnic minority and White groups and in a subset of 
patients who were subsequently admitted to an intensive care unit (ITU).      
Methods
This retrospective observational study was conducted at King’s College Hospital NHS Foundation Trust, 
a busy teaching hospital located in South London. Patients with baseline biochemistry data were 
included in the analysis if they were admitted between the 1st and 28th of April 2020 (the period of 
peak admission rates in London during the first wave of the pandemic), had positive (RT-PCR) SARS-
CoV-2 serology and if ethnicity data was available. The first available result after hospital admission 
for the following 22 biochemical tests were obtained for each patient:  albumin, alkaline phosphatase 
(ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, adjusted 
calcium, CK, creatinine, CRP, estimated glomerular filtration rate (eGFR), ferritin, gamma-glutamyl 
transferase (GGT), LDH, magnesium, sodium, N-terminal prohormone of brain natriuretic peptide (NT-
proBNP), procalcitonin, phosphate, potassium, troponin T, total protein and urea. Inclusion of 
admission biochemical data in the ITU analyses was made if the individual was subsequently 
transferred to ITU within 28 days of admission.  Electronic patient records were accessed for body 
mass index (BMI) data and to assess for the presence of pre-existing common comorbidities in each 
patient at baseline (defined as histories of diabetes mellitus, cardiovascular disease (CVD), chronic 
kidney disease (CKD), hypertension and chronic obstructive pulmonary disease ((COPD) or asthma). 
Patients were classified as "White" or "ethnic minority" using the Office for National Statistics list of 
ethnic groups.  All biochemical data were generated using Roche c-702 and e-801 analytical platforms 
(Roche, Burgess Hill, U.K.), using blood samples collected into serum separator tubes (Greiner Bio-One 
Ltd, Stonehouse, U.K.). All tests are accredited by the United Kingdom Accreditation Service to 
iso15189. The methods used for ALT and AST included pyridoxal phosphate, with the LDH assay being 
measured in the L‑lactate to pyruvate direction. Test requests on samples for which haemolysis, icteric 
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or lipaemic indices exceeded the manufacturer’s limits for that particular test were cancelled and not 
included in analyses. Biochemical test data were tested for normality using the Kolmogorov-Smirnov 
test, and with the exception of albumin, adjusted calcium, globulin, LDH, magnesium, potassium and 
total protein, were found to be not normally distributed so group comparisons of biochemical data 
were made using a two tailed Mann-Whitney U test. Data are reported as median (interquartile 
range). Values of P < 0.05 were taken as statistically significant. The proportion of abnormal results 
for each test studies was compared using a Chi-square test. Data comparisons were made using R 
version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).13  
 
Results
Ethnic minority patients presenting in April 2020 with COVID-19, in comparison to those from White 
ethnic groups, were younger (median age 65 vs. 75 years) and predominantly male (64% vs. 52%, Table 
1).  Ethnic minority individuals were more likely to subsequently require ITU admission (19% patients 
vs. 13% White patients, Table 1). A history of diabetes mellitus was more common in the ethnic 
minority group, whilst CVD history was more common in the White group. Frequencies of 
hypertension, CKD and respiratory disorders (COPD or asthma) were similar in ethnic minority and 
White groups (Table 1). BMI data was incomplete across the two groups. Of available data (151/211 
ethnic minority patients and 70/100 White patients), BMI was similar in the two groups. Median BMI 
(interquartile range) in the ethnic minority group was 28.8 kg/m2 (24.7 – 33.5) and in the White group 
28.7 kg/m2 (23.3 – 32.0).
Review of baseline biochemistry data for all patients revealed statistically significant differences 
between the two groups for a number of common analytes (Table 2). Of these results, 86% were 
obtained on hospital admission day, with 97% of test results being acquired within the first 3 days of 
the patients hospital stay. The majority of patients in the study had abnormal CRP results, however, 
CRP concentrations were higher in the ethnic minority group (median value 111.2 mg/L, interquartile 
Page 8 of 19
https://mc.manuscriptcentral.com/jclinpathol





























































Confidential: For Review Only
range 66.5 – 181.1) than in the White group (48.1 mg/L, 22.1 – 112.9). Increase of this inflammatory 
marker was not reflected by ethnicity-related differences in procalcitonin, nor ferritin concentration; 
almost all patients had elevated ferritin. The median cardiac troponin T was higher, and a greater 
proportion of patients had abnormal results, in the White group than in the ethnic minority group. 
Median NT-proBNP concentration was also higher in the White group, although this association did 
not reach statistical significance.  Of markers of liver function, AST and GGT were higher in the ethnic 
minority group, but ALP lower. A greater proportion of the ethnic minority population also had AST 
concentrations falling outside the reference interval. ALT, albumin and total bilirubin were not 
different between the two groups.  No differences between ethnic minority and White groups were 
noted for sodium, potassium, adjusted calcium or phosphate, nor for markers of renal function 
(creatinine, eGFR and urea). The tissue damage markers, LDH and CK, also showed no ethnicity-specific 
differences at presentation, with the majority of patients having abnormal values. 
When baseline biochemistry data for ethnic minority and White patients that were subsequently 
admitted to ITU were compared, no statistically significant differences between these groups were 
observed for any of the analytes studied (Table 3). 
Discussion
For the first time, we have shown that there are significant differences at hospital presentation 
between ethnic minority and White populations in results for a number of routine biochemistry tests. 
The results of this study are therefore important because they may contribute towards greater 
understanding of why ethnic minority individuals are at increased risk of death due to COVID-19.  The 
most striking finding from our study is the increase at presentation of CRP in ethnic minority 
individuals versus White individuals. CRP measurement is now well established as a marker of disease 
severity in COVID-19.14 Zhang et al.15 showed that in 140 hospitalized patients with confirmed SARS-
CoV-2 infection, in non-severe disease CRP concentrations ranged from 9.5–52.1 mg/L, whilst in 
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severe disease values ranged from 20.6–87.1 mg/L. In another study, 56.4% of patients with non-
severe COVID-19 had CRP above the reference interval, which rose to 81.5% in those with severe 
disease.16  Around 20% of patients infected with SARS-CoV-2 progress to having associated life-
threatening complications involving acute inflammation associated with a cytokine storm, 
coagulopathy, septic shock and multiple organ failure.17 Increased concentrations of interleukin-6 (IL-
6) are associated with severe COVID-19 and positively correlate with adverse outcomes.18,19  The 
increased concentrations of IL-6 directly result in the liver increasing synthesis of CRP.18  The results 
from this study raise the interesting possibility that the higher concentrations of CRP in ethnic minority 
patients at hospital presentation may mark an increased susceptibility to severe inflammation during 
their COVID-19 disease course. These differences appear not to be accounted for by a genetic 
predisposition of ethnic minority individuals to higher CRP levels; median value of CRP in Blacks was 
3.0 mg/L vs. 2.3 mg/L in Whites in one study of healthy individuals.20 The absence of differences 
between the ethnic minority and White groups for the two other markers of inflammation studied 
(procalcitonin and ferritin) supports the hypothesis of a specific increased susceptibility to cytokine-
mediated adverse incidents in the ethnic minority population.21 Pre-existing comorbidities including 
CVD, COPD, diabetes and hypertension are established risk factors for severe disease in the 
pandemic22.  Many of these comorbidities are known to promote a pro-inflammatory state, but of 
these, only diabetes mellitus prevalence was higher in the ethnic minority group than in the White 
group in our study. It is hypothesised that existing diabetes mellitus may accentuate the inflammation 
associated with viral infection23, therefore the increased prevalence of diabetes in the ethnic minority 
group in our study may be a contributory factor to the increased CRP concentrations at presentation 
in this group. Like CRP, diabetes has also been shown to be significantly associated with in-hospital 
mortality24.
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Liver injury in COVID-19 is also associated with disease severity25. It is characterised by increased 
transminases, with increase of AST dominating over ALT5. In our study, AST tended to be higher in the 
ethnic minority population than in the White population whilst ALT did not show any difference 
between the two groups. However, the increases of transminases seen in both groups were generally 
mild and unlikely to represent significant liver injury. Although GGT tended to be higher in the ethnic 
minority population, this difference is likely related to known ethnic differences in this marker.26 We 
have previously reported higher, troponin T and NT-ProBNP in the White population than in ethnic 
minorities12, although the latter association did not reach statistical significance. Likely contributory 
factors to these findings are that the White population were older with a higher prevalence of CVD. 
Elevated troponin has been associated with worse outcomes in COVID-1927.  
In our cohort, although non-White ethnicity and male gender were predictive of ITU admission, no 
statistically significant differences in biochemistry at presentation were noted for those who were 
subsequently admitted to ITU compared to the White population, including for CRP. This may suggest 
that there is no difference in the pathological mechanisms underlying severe COVID-19 which are 
reflected by routine biochemistry, but that ethnic minority subjects are at an increased risk of 
developing them.19 Of course, the association between ethnic minority and severe COVID-19 disease 
is likely to be complex and incorporate multiple demographic and socioeconomic factors not already 
captured in this study.  In one study, Raisi-Estabragh et al.28 suggested that both the sex and ethnic 
patterns of COVID-19 are not adequately explained by variation in cardio-metabolic factors, 25(OH)-
vitamin D concentrations or socio-economic factors; clearly there is a need for more research required 
to define the mechanism of increased ethnic minority risk. 
This study has some limitations. Although the facts that 86% of total test results were obtained on 
admission day and 97% within three days of admission would argue against the possibility of 
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differences in care between ethnic groups whilst in hospital, we cannot exclude the possibility that 
biochemical differences are not contributed to by variance in the disease stage at which different 
ethnic groups accessed hospital care. In the patients who were admitted to ITU during their hospital 
stay, the number of results for some tests may be too low to identify true differences between the 
two groups. The outcomes of ITU patients (requirement for mechanical ventilation/continuous 
positive airway pressure support and morbidity/mortality) were also not available to allow 
interrogation of the biochemistry with respect to endpoint. In addition, the majority of the ethnic 
minority group were of Black ethnicity, (149/211 of all ethnic minority cases, all ethnic minority 
individuals in ITU), so caution is advised in making generalisations across all non-White ethnic groups. 
Finally, for some tests in the study, such as procalcitonin, only a small number of tests were performed 
overall.    
In conclusion, the major finding of this study is that ethnic minority patients have higher CRP 
concentrations at presentation, indicating a more severe acute inflammation. This may augment 
existing co-morbidities characterised by chronic inflammation which may be more prevalent in the 
ethnic minority population such as diabetes, pointing towards an increased tendency for severe 
inflammation in this group. 
Key messages:
 In the U.K, it has been shown that ethnic minorities have poorer outcomes in COVID-19 
relative to those of the White population, including an increased risk of death 
 In this study, we show that there are significant differences between ethnic minority and 
White populations in routine clinical biochemistry parameters at presentation to hospital 
with COVID-19
 Amongst the markers identified, C-reactive protein was significantly higher in the ethnic 
minority group, pointing towards an increased tendency for severe inflammation in this 
group, which may contribute towards the poorer outcomes in this group reported previously
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Tables




Age (years) 65 (55-78) 75 (66-84)
Male/female (%) 64/36 52/48
Pre-existing comorbidities:
Diabetes (%) 54 31
CVD (%) 25 50
CKD (%) 31 28
Hypertension (%) 49 49
COPD/Asthma (%) 30 27
Patients subsequently admitted to intensive care
Number (% total) 39 (18) 13 (13)
Age (years) 59 (52-65) 65 (57-71)
Male/female (%) 77/23 77/23
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Table 2. Biochemistry at presentation (all patient data). P values <0.05 were taken as statistically significant. N/A = Chi-squared test was not applicable to 
data where only abnormal results were recorded.
Test Number of results Test result (Median (interquartile range)) Abnormal results (%)
Ethnic 
minority
White Ethnic minority White P-value Ethnic 
minority
White P-value
Albumin (g/L) 211 100 37.0 (34.0 – 39.5) 37.5 (34.0 – 41.0) 0.247 30 33 0.668
ALP (IU/L) 209 100 74.0 (57.0 – 98.0) 84.0 (63.0 – 102.5) 0.039 12 17 0.302
ALT (IU/L) 104 33 41.0 (27.8 – 58.0) 32.0 (17.0 – 70.0) 0.078 29 27 1.000
AST (IU/L) 206 99 52.0 (35.2 – 76.0) 40.0 (28.0 – 71.5) 0.008 75 56 0.001
Total bilirubin (µmol/L) 211 100 9.0 (6.5 – 13.0) 9.0 (6.0 – 14.0) 0.617 6 6 1.000
Adjusted calcium (mmol/L) 183 81 2.3 (2.2 – 2.4) 2.3 (2.2 -2.4) 0.537 19 22 0.604
CK (IU/L) 63 31 270.0 (111.5 – 
1139.0)
163.0 (63.5 – 725.0) 0.447 67 52 0.236
Creatinine (µmol/L) 211 100 106.0 (80.0 – 159.5) 100.0 (76.8 – 138.5) 0.208 40 35 0.442
CRP (mg/L) 209 98 111.2 (66.5 – 181.1) 48.1 (22.1 – 112.9) <0.001 97 93 0.153
eGFR (ml/min/1.73m2) 210 99 58.0 (34.0 – 78.8) 55.0 (38.5 – 86.0) 0.447 56 65 0.222
Ferritin (µg/L) 91 35 916.0 (579.0 – 
1815.5)
1,046.0 (386.5 – 
1859.0)
0.208 90 86 0.699
GGT (IU/L) 209 100 57.0 (32.0 – 99.0) 41.0 (23.0 – 83.2) 0.030 51 40 1.000
LDH (IU/L) 48 12 467.0 (351.2 – 631.2) 503.5 (457.5 – 634.0) 0.432 92 92 1.000
Magnesium (mmol/L) 183 81 0.9 (0.8 – 1.0) 0.8 (0.8 – 1.0) 0.028 28 32 0.582
Sodium (mmol/L) 211 100 137.0 (134.0 – 140.0) 137.0 (134.0 – 140.30) 0.521 35 35 1.000
NT-proBNP (ng/L) 34 13 221.5 (90.8 – 1077.5) 427.0 (141.0 – 1678.0) 0.274 66 77 0.448
Procalcitonin (µg/L) 28 8 1.2 (0.4 – 11.4) 0.7 (0.3 – 2.5) 0.594 100 100 N/A
Phosphate (mmol/L) 181 81 1.0 (0.8 – 1.2) 1.0 (0.9 – 1.2) 0.145 36 30 0.395
Potassium (mmol/L) 208 98 4.2 (3.8 – 4.7) 4.3 (3.9 – 4.8) 0.215 24 19 0.502
Troponin T (ng/L) 122 45 19.0 (8.2 – 52.2) 35.0 (16.0 – 74.0) 0.023 62 82 0.024
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Total protein (g/L) 210 100 71.0 (67.0 – 74.0) 68.5 (64.0 – 71.2) <0.001 12 13 0.929
Urea (mmol/L) 211 99 7.0 (4.6 – 14.3) 8.7 (5.9 – 13.9) 0.059 64 67 0.738
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Table 3. Biochemistry at hospital presentation in patients subsequently admitted to intensive care. P values <0.05 were taken as statistically significant. N/A 
= Chi-squared test was not applicable to data where only abnormal results were recorded.
Test Number of results Test result (Median (interquartile range)) Abnormal results (%)
Ethnic 
minority








Albumin (g/L) 39 13 38.0 (34.0 – 39.0) 35.0 (32.0 – 37.0) 0.167 28 38 0.729
ALP (IU/L) 39 13 81.0 (57.0 – 107.0) 83.0 (74.0 – 132.0) 0.459 21 31 0.704
ALT (IU/L) 36 10 44.5 (30.0 – 68.5) 76.0 (41.0 – 154.5) 0.432 36 50 0.667
AST (IU/L) 39 13 68.0 (48.5 – 136.0) 65.0 (44.0 – 183.0) 0.966 87 77 0.657
Total bilirubin (µmol/L) 39 13 8.0 (7.0 – 13.0) 11.0 (8.0 – 18.0) 0.203 5 23 0.175
Adjusted calcium (mmol/L) 39 13 2.3 (2.2 – 2.4) 2.3 (2.2 – 2.3) 0.958 23 31 0.853
CK (IU/L) 29 10 632.0 (161.0 – 1687.0) 142.5 (83.2 – 1174.2) 0.311 79 40 0.054
Creatinine (µmol/L) 39 13 110.0 (81.0 – 211.0) 130.0 (110.0 – 182.0) 0.310 41 62 0.335
CRP (mg/L) 39 13 157.0 (111.4 – 257.1) 168.4 (40.9 – 251.8) 0.616 100 100 N/A
eGFR (ml/min/1.73m2) 39 13 59.0 (28.0 – 83.0) 39.0 (32.0 – 58.0) 0.295 51 85 0.073
Ferritin (µg/L) 34 10 1,054.5 (718.0 – 
1981.0)
1,822.0 (1018.2 – 
2507.5)
0.245 97 90 0.937
GGT (IU/L) 39 13 91.0 (46.0 – 136.0) 66.0 (48.0 – 100.0) 0.512 72 69 1.000
LDH (IU/L) 28 6 522.5 (399.8 – 687.0) 500.5 (402.2 – 672.2) 0.878 96 100 1.000
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Magnesium (mmol/L) 39 13 0.9 (0.9 – 1.0) 1.0 (0.8 – 1.1) 0.657 33 46 0.618
Sodium (mmol/L) 39 13 136.0 (134.0 – 139.0) 137.0 (136.0 – 138.0) 0.367 38 23 0.501
NT-proBNP (ng/L) 23 5 400.0 (164.5 – 1867.0) 427.0 (126.0 – 3916.0) 0.676 74 80 1.000
Procalcitonin (µg/L) 22 8 1.6 (0.5 – 11.8) 0.7 (0.3 – 2.5) 0.241 100 100 N/A
Phosphate (mmol/L) 39 13 1.1 (0.8 – 1.5) 1.2 (1.0 – 1.7) 0.336 46 54 0.873
Potassium (mmol/L) 39 13 4.4 (4.0 – 4.9) 4.7 (3.8 – 5.4) 0.695 28 38 0.729
Troponin T (ng/L) 35 12 24.0 (14.5 – 54.0) 32.0 (16.0 – 90.2) 0.472 74 92 0.389
Total protein (g/L) 39 13 72.0 (67.0 – 73.0) 66.0 (60.0 – 71.0 0.044 8 15 0.786
Urea (mmol/L) 39 13 8.6 (5.0 – 15.2) 17.6 (9.9 – 19.1) 0.076 59 85 0.178
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